MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

We recently published 10 Stocks Jim Cramer Talked About. Moderna Inc. (NASDAQ:MRNA) is one of the stocks on Jim Cramer talked ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

At the 44 th Annual JP Morgan Healthcare Conference on Monday, Moderna Inc. (NASDAQ:MRNA) said that it expects to report ...

Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company’s value has increased by approximately $1.2 billion over ...

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving from 1.90% in May to 1.96%, indicating a collective rise in negative bets ...

Shares of Moderna MRNA declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing seeking the FDA’s approval for mRNA-1083, its investigational mRNA-based ...